Construction of a Risk Screening Tool for New Psychoactive Substance Misuse Among Adolescents and Young Adults

December 13, 2024 updated by: Wei XIA, PhD

The goal of this observational study is to construct a risk tool available for screening young adults and adolescents at high risk of drug misuse and provides a chance for early intervention to young adults and adolescents at high risk of drug misuse, which prevent the onset and development of drug addiction in the future.The main question it aims to answer is:

  1. Explore the occurrence and influencing factors of new psychoactive substance misuse among young adults and adolescents;
  2. Construct a risk prediction model for new psychoactive substance misuse among young adults and adolescents and conduct internal verification of the model;
  3. Based on the results of the prediction model, select the optimal model to initially form a concise scale "Screening Tool for the Risk of New Psychoactive Substance Misuse among Young Adults and Adolescents";
  4. Conduct external verification of the tool, and revise and improve the screening tool, form the final version of the screening tool, and verify the application performance of the screening tool.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1035

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510080

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Adolescents and young adults aging 14-35 years old

Description

Inclusion Criteria:

  • Adolescents and young adults who were aged 14-35 years;
  • Adolescents and young adults could read and communicate in Chinese were invited to participate in this study

Exclusion Criteria:

  • Adolescents and young adults who were unable to complete the questionnaire due to physical or psychological reasons.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived risks associated with drug abuse
Time Frame: baseline
Perceived risks associated with drug abuse developed by the Hong Kong Security Bureau's Narcotics Division is adopted (https://www.nd.gov.hk/tc/beat_questions_2010R2.html). The scale consists of 12 questions and uses a 5-point Likert scale (1 = Strongly Disagree, 2 = Disagree, 3 = Unsure, 4 = Agree, 5 = Strongly Agree). The total score ranges from 12 to 60, with a higher score indicating a greater awareness of drug use risks. In this study, the Cronbach's α coefficient for the Chinese version of this scale is 0.931.
baseline
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: baseline
The Pittsburgh Sleep Quality Index was developed by Buysse et al. [14], and the Chinese version was translated and revised by Xianchen Liu et al. in 1996 [15]. It has been confirmed that the PSQI is suitable for evaluating sleep quality in patients with mental disorders and the general population in China. This scale consists of 19 self-reported items and 5 observer-rated items, of which the 19th self-reported item and the 5 observer-rated items are not included in the scoring. The 18 items comprise seven factors: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. Each component is scored on a scale from 0 to 3, with a total score range from 0 to 21. A higher score indicates poorer sleep quality. In this study, the overall Cronbach's α coefficient for the Chinese version of the scale across the seven factors was 0.716.
baseline
Prosocial Tendencies Measure (PTM)
Time Frame: baseline
The Chinese version of the Prosocial Tendencies Measure was revised by Yu Kou, Huifang Hong et al. in 2007 [16]. This scale consists of 26 items, encompassing six dimensions: public, anonymous, altruistic, compliant, emotional, and urgent. It uses a 5-point Likert scale for scoring (1 = very unlike me, 2 = somewhat unlike me, 3 = neutral, 4 = somewhat like me, 5 = very like me). The total score ranges from 26 to 130, with higher scores indicating greater prosocial tendencies. In this study, the Cronbach's α coefficient for the Chinese version of the scale was 0.957, with the Cronbach's α coefficients for the six dimensions of public, anonymous, altruistic, compliant, emotional, and urgent being 0.824, 0.877, 0.845, 0.849, 0.855, and 0.791, respectively.
baseline
Achenbach Youth Self Report (YSR)
Time Frame: baseline
The Youth Self Report (YSR), developed by Achenbach et al. [17], was used in its 2001 version. The Chinese version was translated and revised by Wang Runcheng et al.[18] in 2013. The questionnaire is divided into 8 factors (Anxiety/Depression, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Delinquent Behavior, Aggressive Behavior) and an "Other Problems" item. The Delinquent Behavior and Aggressive Behavior factors together constitute the externalizing symptom group and are widely used to measure externalizing problem behaviors in adolescents. The Delinquent Behavior factor includes 15 items, and the Aggressive Behavior factor includes 17 items, using a three-point scoring scale (0 = not at all true, 1 = somewhat true, 2 = very true). The total score for the two factors ranges from 0 to 96, with higher scores indicating more severe externalizing problem behaviors. In this study, the Cronbach's α coefficients for the Delinquent Behavior
baseline
Brief Sensation Seeking Scale for Chinese (BSSS-C)
Time Frame: baseline
The 8-item Brief Sensation Seeking Scale developed by Hoyle et al.[19] was utilized, with the Chinese version translated and revised by Xinguang Chen et al.[20] in 2013 to measure personality traits related to sensation seeking. This scale comprises 8 items, encompassing four dimensions: Lack of Self-Control, Pursuit of Novelty, Difficulty Tolerating Monotony, and Pursuit of New Experiences. A five-point Likert scale was used for scoring (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree). The total score ranges from 8 to 40, with higher scores indicating higher levels of sensation seeking. In this study, the Cronbach's α coefficient for the Chinese version of the scale was 0.855.
baseline
Power of Food Scale (PFS)
Time Frame: baseline
The Power of Food Scale developed by Lowe et al.[21] was employed, with the Chinese version translated and revised by Han Xiao, Jianwen Song, Xinni Han et al.[22] in 2023, to measure the level of hedonic hunger. The scale consists of 15 items, which include three dimensions: Food Availability, Food Presence, and Food Taste, utilizing a five-point Likert scale for scoring (1 = I disagree, 2 = I somewhat agree, 3 = I somewhat agree, 4 = I fairly agree, 5 = I completely agree). The total score ranges from 15 to 75, with higher total scores indicating a greater level of hedonic hunger. In this study, the Cronbach's α coefficient for the Chinese version of the scale was 0.940, and the Cronbach's α coefficients for the three dimensions (Food Availability, Food Presence, Food Taste) were 0.866, 0.858, and 0.863, respectively.
baseline
Permissive attitude towards drug abuse
Time Frame: baseline
Permissive attitude towards drug abuse developed by the Hong Kong Security Bureau's Narcotics Division is adopted (https://www.nd.gov.hk/tc/beat_questions_2010R2.html). The scale consists of 21 questions and uses a 5-point Likert scale (1 = Strongly Disagree, 2 = Disagree, 3 = Unsure, 4 = Agree, 5 = Strongly Agree). The total score ranges from 21 to 105, with a higher score indicating a higher tolerance attitude towards drug use. In this study, the Cronbach's α coefficient for the Chinese version of this scale is 0.966.
baseline
Refusal Self-Efficacy Scale (Self-Efficacy List for Drug Users, SELD)
Time Frame: baseline
The Refusal Self-Efficacy Scale developed by Gerdien et al.[23] is adopted (Self-Efficacy List for Drug Users, SELD), with the Chinese version translated and revised by Liuna Geng et al.[24], used to measure refusal self-efficacy regarding drugs. The scale consists of 17 questions encompassing three dimensions: environmental factors, negative emotions, and positive emotions, using a 5-point Likert scale (1 = Very Easy to Refuse, 2 = Easy to Refuse, 3 = Unsure, 4 = Somewhat Difficult to Refuse, 5 = Very Difficult to Refuse). The total score ranges from 17 to 85, with a higher score indicating lower refusal self-efficacy. In this study, the Cronbach's α coefficient for the Chinese version of this scale is 0.961, and the Cronbach's α coefficients for the three dimensions (environmental factors, negative emotions, positive emotions) are 0.901, 0.928, and 0.937, respectively.
baseline
Adverse childhood experiences, ACEs
Time Frame: baseline
The Adverse Childhood Experiences Scale developed by the Kaiser-CDC laboratory is adopted to investigate various adverse events experienced by subjects before the age of 18[25]. The scale includes three dimensions: abuse, neglect, and family dysfunction, with a total of 10 items. Each item offers two response options: "Yes" and "No." A "Yes" response is scored as 1 point, while a "No" response is scored as 0 points. The total score is the sum of the scores from each item, reflecting the number of adverse childhood experiences. The total score ranges from 0 to 10, with a higher score indicating more adverse childhood experiences. In this study, the Cronbach's α coefficient for the Chinese version of this scale is 0.760.
baseline
Peers drug-misuse situation
Time Frame: baseline
It is a binary outcome. The investigators will ask for question that "Are there peers around you engage in drug use?" And the participants are supposed to answer "yes" or "no"
baseline
Work experiences in special venues
Time Frame: baseline
The investigators will ask for question that "Do you have any work experience in special venues such as bars or nightclubs?" And the participants are supposed to choose the special venues they used to work including "Bar", "Internet cafe", "Ballroom", "Nightclub", "KTV", "Disco", "Leisure clubhouse", "Agriturismo" or choose "None of the above" if they have never work in such special venues.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2024

Primary Completion (Estimated)

August 15, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

November 27, 2024

First Submitted That Met QC Criteria

November 27, 2024

First Posted (Actual)

December 3, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 13, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • L2024SYSU-HL-039

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe